Suven Pharmaceuticals Shares Rise 2.1% on Strong Q3 Profit Growth

Suven Pharmaceuticals shares climbed 2.1% in pre-open trade on February 13, 2025, after the company reported a robust 77.1% year-on-year increase in Q3 FY25 net profit to ₹82.9 crore. Revenue surged 39.8% to ₹307.2 crore, driven by exceptional growth in its pharma CDMO business, which rose 101%. EBITDA soared 78.2% to ₹117.8 crore, with margins expanding to 38.4%. Strategic additions of new molecules and partnerships with global pharma leaders further bolstered investor confidence in the company's growth trajectory.

 

Sources: Moneycontrol, Economic Times, CNBC-TV18